Alison M. Weppler

884 total citations
24 papers, 294 citations indexed

About

Alison M. Weppler is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Alison M. Weppler has authored 24 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Alison M. Weppler's work include Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (6 papers) and Melanoma and MAPK Pathways (6 papers). Alison M. Weppler is often cited by papers focused on Cancer Immunotherapy and Biomarkers (16 papers), CAR-T cell therapy research (6 papers) and Melanoma and MAPK Pathways (6 papers). Alison M. Weppler collaborates with scholars based in Australia, United States and France. Alison M. Weppler's co-authors include Shahneen Sandhu, George Au‐Yeung, Georgina V. Long, Matteo S. Carlino, Célèste Lebbé, Peter K. H. Lau, Rodney J. Hicks, Alexander M. Menzies, Amir Iravani and Roslyn Wallace and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Radiology.

In The Last Decade

Alison M. Weppler

22 papers receiving 291 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison M. Weppler Australia	9	233	63	62	62	58	24	294
Xiaoyi Duan China	12	128 0.5×	104 1.7×	63 1.0×	65 1.0×	56 1.0×	31	371
Emanuela Romano France	10	207 0.9×	119 1.9×	51 0.8×	105 1.7×	43 0.7×	45	320
Ivonne Vázquez Spain	11	124 0.5×	21 0.3×	56 0.9×	98 1.6×	37 0.6×	27	357
Laetitia Da Meda France	8	206 0.9×	47 0.7×	49 0.8×	44 0.7×	14 0.2×	24	254
Konstantinos Rounis Greece	11	228 1.0×	100 1.6×	82 1.3×	42 0.7×	75 1.3×	24	341
Joaquín Mosquera Spain	12	305 1.3×	226 3.6×	53 0.9×	23 0.4×	71 1.2×	39	457
Chunji Chen China	10	96 0.4×	114 1.8×	188 3.0×	33 0.5×	109 1.9×	31	361
Lauren Nye United States	9	270 1.2×	76 1.2×	58 0.9×	46 0.7×	115 2.0×	37	369
Huiyu Lu China	11	144 0.6×	82 1.3×	120 1.9×	23 0.4×	76 1.3×	29	303
Francesca Comito Italy	10	131 0.6×	113 1.8×	77 1.2×	26 0.4×	79 1.4×	26	331

Countries citing papers authored by Alison M. Weppler

Since Specialization

Citations

This map shows the geographic impact of Alison M. Weppler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison M. Weppler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison M. Weppler more than expected).

Fields of papers citing papers by Alison M. Weppler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison M. Weppler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison M. Weppler. The network helps show where Alison M. Weppler may publish in the future.

Co-authorship network of co-authors of Alison M. Weppler

This figure shows the co-authorship network connecting the top 25 collaborators of Alison M. Weppler. A scholar is included among the top collaborators of Alison M. Weppler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison M. Weppler. Alison M. Weppler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krebs, Emanuel, Deirdre Weymann, Cheryl Ho, et al.. (2025). Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation. JCO Precision Oncology. 9(9). e2400631–e2400631. 1 indexed citations

Angeles, Arkhjamil, Thao Phuong Nguyen, Gaurav Bahl, et al.. (2024). Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors.. Journal of Clinical Oncology. 42(16_suppl). 12047–12047. 2 indexed citations

Weppler, Alison M., Laetitia Da Meda, Inês Pires da Silva, et al.. (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. European Journal of Cancer. 183. 109–118. 14 indexed citations

Iravani, Amir, Roslyn Wallace, Serigne Lo, et al.. (2023). FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. Radiology. 307(3). e221180–e221180. 11 indexed citations

Lau, Peter K. H., S.J. Harris, Melissa Eastgate, et al.. (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9525–9525. 1 indexed citations

Iravani, Amir, Arian Lasocki, Roslyn Wallace, et al.. (2023). Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis. Frontiers in Endocrinology. 14. 1295865–1295865. 4 indexed citations

Pizzolla, Angela, Simon P. Keam, Ismael A. Vergara, et al.. (2022). Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. Journal for ImmunoTherapy of Cancer. 10(5). e004574–e004574. 19 indexed citations

Atkinson, Victoria, Prachi Bhave, Alison M. Weppler, et al.. (2021). Management of resected stage III/IV melanoma with adjuvant immunotherapy.. Journal of Clinical Oncology. 39(15_suppl). 9571–9571.

Weppler, Alison M., Laetitia Da Meda, Inês Pires da Silva, et al.. (2021). Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.. Journal of Clinical Oncology. 39(15_suppl). 9543–9543.

10.

Brown, Lauren, Alison M. Weppler, Prachi Bhave, et al.. (2021). Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. Journal for ImmunoTherapy of Cancer. 9(5). e002121–e002121. 45 indexed citations

11.

Lee, Jenny, Alexander M. Menzies, Matteo S. Carlino, et al.. (2020). Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research. 26(15). 4064–4071. 62 indexed citations

12.

Weppler, Alison M., Andrew Pattison, Prachi Bhave, et al.. (2020). Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. Journal for ImmunoTherapy of Cancer. 8(2). e000700–e000700. 8 indexed citations

13.

Brown, Lauren, Alison M. Weppler, Prachi Bhave, et al.. (2020). Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).. Journal of Clinical Oncology. 38(15_suppl). 10026–10026. 3 indexed citations

14.

Versluis, Judith M., Alison M. Weppler, Lauren Brown, et al.. (2020). 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition. Annals of Oncology. 31. S733–S734. 1 indexed citations

15.

Iravani, Amir, Medhat Osman, Alison M. Weppler, et al.. (2020). FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. European Journal of Nuclear Medicine and Molecular Imaging. 47(12). 2776–2786. 49 indexed citations

16.

Pizzolla, Angela, Simon P. Keam, Ismael A. Vergara, et al.. (2020). 548 CD8+ tissue-resident memory T cells are tumour reactive and increase after immunotherapy in a case of metastatic mucosal melanoma. SHILAP Revista de lepidopterología. A333.1–A333. 1 indexed citations

17.

Delisle, Megan, et al.. (2020). Refusal of colorectal cancer surgery in the United States: Predictors and associated cancer-specific mortality in a Surveillance, Epidemiology, and End Results (SEER) cohort. Surgery Open Science. 2(4). 12–18. 10 indexed citations

18.

Iravani, Amir, Arian Lasocki, Roslyn Wallace, et al.. (2020). SUN-127 Diagnostic Challenges Associated with the Rising Incidence of Endocrine Toxicity in the Era of Combination Immunotherapy. Journal of the Endocrine Society. 4(Supplement_1). 1 indexed citations

19.

Guo, Christina, Marliese Alexander, Peter K. H. Lau, et al.. (2019). A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. European Journal of Cancer. 124. 15–24. 35 indexed citations

20.

Iravani, Amir, Medhat Osman, Michael S. Hofman, et al.. (2019). Response assessment and immune-related adverse events as detected by FDG PET/CT in patients treated with combined CTLA-4 and PD-1 checkpoint inhibitors as first-line therapy in advanced melanoma. 60. 647–647. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact